Interleukin-6 inhibitors (tocilizumab or sarilumab) for adult patients hospitalised due to COVID-19, DHSC (updated 29th November 2022)

Published policy has been updated following recommendations of the updated WHO clinical guideline. An IL-6 inhibitor may be administered in combination with baricitinib (as well as corticosteroids, unless contraindicated) as per clinical judgement in severe or critical COVID-19.
Source: Current Awareness Service for Health (CASH) - Category: Consumer Health News Source Type: news